Magnetic Resonance-Guided Adaptive Radiotherapy (MRgART) Using an Integrated Magnetic Resonance Linear Accelerator (MRL)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cancer
- Sponsor
- University Health Network, Toronto
- Enrollment
- 377
- Locations
- 1
- Primary Endpoint
- Complication rates measured using the Common Toxicity Criteria for Adverse Events
- Status
- Active, not recruiting
- Last Updated
- last month
Overview
Brief Summary
This study is being done to help further understand how MR-guided adaptive RT in conjunction with the Integrated Magnetic Resonance Linear Accelerator (MRL) can improve patient outcomes. This study will include participants who will be receiving radiotherapy using the MRL machine to target their cancer more precisely. Participants will be asked to have a few extra MR scans taken during their RT planning and to complete a few quality of life questionnaires.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients 18 years or older with a diagnosis of cancer, regardless of clinical site or stage
- •Planned to receive a course of MR-guided adaptive RT using the MRL
- •Ability to provide informed consent
Exclusion Criteria
- •Patients under 18 years old
Outcomes
Primary Outcomes
Complication rates measured using the Common Toxicity Criteria for Adverse Events
Time Frame: Within 3 months of completing treatment
Refine our understanding of clinical scenarios where MRgART with the MRL improves patient outcomes and translate this new knowledge and new treatment approach to widespread clinical practice through the development and validation of efficient, cost-effective treatment processes.
Local, regional and distant tumor control rates
Time Frame: Up to 5 years post-radiotherapy
Refine our understanding of clinical scenarios where MRgART with the MRL improves patient outcomes and translate this new knowledge and new treatment approach to widespread clinical practice through the development and validation of efficient, cost-effective treatment processes.
Disease-free and overall survival rates
Time Frame: Up to 5 years post-radiotherapy
Refine our understanding of clinical scenarios where MRgART with the MRL improves patient outcomes and translate this new knowledge and new treatment approach to widespread clinical practice through the development and validation of efficient, cost-effective treatment processes.
Secondary Outcomes
- Patient experience and anxiety related to MR imaging and adaptive RT with the MR(each ambulatory care and radiation treatment review clinic visit (up to 5 years post treatment))
- Patient experience and anxiety related to MR imaging and adaptive RT with the MR(Immediately after first MRL treatment visit)
- Patient experience and anxiety related to MR imaging and adaptive RT with the MR(Immediately after last MRL treatment visit)
- Patient experience and anxiety related to MR imaging and adaptive RT with the MR(d prior to starting treatment with the MRL, immediately after the last MRL treatment, at the first follow-up visit and annually thereafter during follow-up (up to 5 years post treatment))